Physician profile
John C Wates
NPI 1639284938
$3,148.19
in general payments reported to CMS, 2019-2025
23 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $675 · 2022: $828 · 2023: $845 · 2024: $394 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,645.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $572.53 | 2021-2025 | |
| Lilly USA, LLC | $445.98 | 2021-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $330.54 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $229.30 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $201.23 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $191.89 | 2022-2025 | |
| Abbott Laboratories | $182.47 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $112.85 | 2021-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $111.36 | 2021-2025 | |
| Amgen INC. | $110.56 | 2021-2025 | Evenity, Prolia, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.04 | 2021-2023 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $88.29 | 2022-2025 | Rexulti |
| Exact Sciences Corporation | $84.59 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $77.03 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.62 | 2021-2023 | Xifaxan, Trulance |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $58.11 | 2021-2023 | Arexvy, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $48.77 | 2021 | |
| Merck Sharp & Dohme LLC | $44.17 | 2021-2025 | Verquvo |
| Biohaven Pharmaceutical Holding Company LTD. | $32.17 | 2022 | |
| Irhythm Technologies, INC. | $21.50 | 2023 | Zio Xt Patch |
| Amarin Pharma, INC. | $15.62 | 2021 | |
| Supernus Pharmaceuticals, INC. | $14.86 | 2025 | Qelbree |
| Idorsia Pharmaceuticals US INC | $14.71 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.